Japan Lifeline : Announces Results of Acquisition of Own Shares and Completion of It and Number of Shares to be Cancelled(135KB)
March 01, 2024 at 06:12 am EST
Share
March 1, 2024
To whom it may concern,
Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO (Code: 7575 TSE Prime Market)
Contact person: Takeyoshi Egawa, Vice President, Business Administration Department
(TEL. +81-3-6711-5200)
Japan Lifeline Announces Results of Acquisition of Own Shares and Completion of It and Number of
Shares to be Cancelled
(Acquisition of Own Shares Under the Provisions of the Articles of Incorporation Pursuant to the
Provisions of Article 165, Paragraph (2) of the Companies Act and Cancellation of Own Shares Under the
Provision of the Article 178 of the Same Act)
Japan Lifeline Co., Ltd. ("the Company") announced as below the results of the acquisition of its own shares pursuant to the provisions of Article 156 of the Companies Act, as applied by replacing the relevant terms pursuant to the provisions of Article 165, paragraph (3) of the same Act. With this acquisition, the Company has completed the acquisition of all own shares based on the resolution of the Board of Directors meeting held on May 10, 2023.
The Company also announced that the number of shares to be cancelled has been determined in accordance with the resolution of the same Board of Directors meeting pursuant to the provisions of Article 178 of the Companies Act.
1. Results of the acquisition of own shares
(1)
Class of shares acquired
: Common shares of the Company
(2)
Total number of shares acquired
: 214,400 shares
(3)
Total amount of shares
: 276,726,392 yen
acquisition costs
(4)
Acquisition period
: February 1, 2024 to February 29, 2024
(5)
Acquisition method
: Market purchase on the Tokyo Stock Exchange
2. Cancellation of own shares
(1)
Class of shares to be cancelled
: Common shares of the Company
(2)
Total number of shares to be
: 7,161,506 shares
cancelled
(3)
Total number of shares
: 74,929,270 shares
outstanding after cancellation
(excluding treasury shares)
(4)
Cancellation date
: March 13, 2024
(Note) The Company has introduced a BIP (Board Incentive Plan) trust, and the Company shares held by the trust are treated as own shares.
1
(Reference)
1. Details of the resolution regarding the acquisition of own shares at the Board of Directors meeting held on May 10, 2023
(1)
Class of shares to be
: Common shares of the Company
acquired
(2)
Total number of shares to
: 3,000,000 shares (maximum)
be acquired
(3.9% of the total number of shares issued excluding own shares)
(3)
Total amount of shares
: 4,000,000,000 yen (maximum)
acquisition costs
(4)
Acquisition period
: May 11, 2023 to February 29, 2024
(5)
Acquisition method
: Market purchase on the Tokyo Stock Exchange
2. Cumulative total of own shares acquired up to February 29, 2024 based on the above resolution
(1)
Total number of shares
: 3,000,000 shares
acquired
(2)
Total amount of shares
: 3,319,770,616 yen
acquisition costs
3. Details of the resolution regarding the cancellation of own shares at the Board of Directors meeting held on May 10, 2023
(1)
Class of shares to be
: Common shares of the Company
cancelled
(2)
Total number of shares to
: Number of shares in excess of 1% of total shares outstanding before
be cancelled
cancellation
(3)
Cancellation date
: March 15, 2024
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
JLL - Japan Lifeline Co. Ltd. published this content on
01 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
01 March 2024 11:12:47 UTC.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.